NIH RePORTER
Cure8 regulatory brief
Mapping REV-ERB?’s Protein Interactions to Understand Th17-mediated Inflammation
Research and clinical trials
Clinical study
Researchers
Clinicians
Inflammatory bowel disease
Crohn's disease
Why This Matters
The study targets REV-ERBα, a regulator of TH17 cells that contribute to Crohn’s disease and ulcerative colitis, so its findings could identify new molecular pathways to target for IBD therapies.
Who Should Pay Attention
Researchers studying immune mechanisms in IBD, clinicians interested in future therapeutic targets for TH17-driven inflammation, and translational scientists working on drug discovery.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
The research uses proximity labeling (MiniTurboID) coupled with proteomics to map proteins that interact with REV-ERBα in primary murine TH17 cells, comparing heme-bound and heme-free conditions.
The team will validate key interactions and map target genes and binding sites with RNA-seq and ChIP-seq, and test functional relevance in vivo with a pooled RNAi screen in a colitis model. The project is a funded research plan (NIH Reporter project record) describing aims and methods rather than reporting final results.
The work is preclinical (mouse cells and murine colitis models) and focused on mechanisms that could inform future therapeutic development.
Keep In Mind
This is a funded NIH project record describing planned preclinical experiments (proteomics, RNA-seq, ChIP-seq, and an RNAi screen) using murine TH17 cells and colitis models; it does not present completed results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsAnna B Schell
InstitutionUNIVERSITY OF FLORIDA
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 1, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - F31DK149568 - $37,114
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
S1PR1 Signaling In The Lymphatic Vasculature Regulates Tertiary Lymphoid Organ Formation
Tertiary lymphoid organs form in IBD and may influence disease course; understanding how lymphatic S1PR1 controls TLOs could reveal new targets to modify intestinal inflammation without broad immunosuppression.
Adaptive Immune Regulation of Enteric Neurogenesis Directs Intestinal Inflammation
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
Integrative Genetic and Proteomic Modeling for Predicting Chronic and Treatment-Induced Autoimmunity
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.